Clinical Trials in China / NCT05204108
Recruiting
Observational
Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography
NCT05204108 · tracked via the Priya Life Science China tracker
Condition(s) studied
Bladder Cancer
Study summary
To evaluate the diagnostic accuracy of CEUS for the preoperative staging of bladder cancer, which would benefit the implementation of efficient therapeutic strategies.
Eligibility
Inclusion Criteria:
* (a) eligible patients should be 18-year-old or older;
* (b) patients should have a histologically or cytologically confirmed diagnosis of primary bladder cancer;
* (c) patients should not have had any surgery, chemotherapy, immunotherapy, or any therapy before CEUS diagnosis.
Exclusion Criteria:
* (a) participants with confirmed to have no carcinoma of the bladder;
* (b) participants with previous pelvic surgery, who had undergone therapy, any bladder surgery, or had received chemotherapy, radiotherapy or immunotherapy;
* (c) participants diagnosed with tumor recurrence or metastasis; (d) participants who were allergic to ultrasound contrast agents or could not tolerate CEUS examination, for instance, with recent myocardial infarction, angina pectoris, cardiac insufficiency, severe cardiac arrhythmia, a right/left cardiac shunt, severe pulmonary hypertension, uncontrolled systemic hypertension, acute respiratory distress syndrome, or chronic obstructive pulmonary disease.
Primary outcome measure(s)
- Detection of Muscle Invasion in Bladder Cancer — within 3 minutes
To evaluate the preoperative staging of bladder cancer,whether it is non-muscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancers (MIBC)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou | Guangdong | Recruiting |
More Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials in China
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05204108 on ClinicalTrials.gov ↗ ← All trials in China